ATTENTION AKERO THERAPEUTICS, INC. (AKRO) SHAREHOLDERS: GRABAR LAW OFFICE IS INVESTIGATING CLAIMS OF POSSIBLE MISCONDUCT ON YOUR BEHALF

Have You Continuously Held Akero Therapeutics Shares Since Before September 13, 2022?

Philadelphia, Pennsylvania--(Newsfile Corp. - October 14, 2024) - Grabar Law Office is investigating potential breach of fiduciary duties by Akero Therapeutics, Inc. (NASDAQ: AKRO). If you have held Akero shares since prior to September 13, 2022, you may have the right to:

• Demand corporate reforms to improve governance.
• Recover funds expended by the company defending class action litigation.
• Receive a court-approved incentive award, all at no cost to you.

Learn More Today:
https://grabarlaw.com/the-latest/akero-shareholder-investigation/
Or contact Joshua Grabar at 267-507-6085 for a free consultation.

What Is the Investigation About?

A recent securities fraud class action complaint alleges that Akero Therapeutics misled investors regarding the SYMMETRY clinical trial for its NASH treatment. The complaint outlines several critical issues:

1. 20% of clinical trial patients had cryptogenic cirrhosis, not definitive NASH, at baseline.
2. These patients lacked biopsy-proven compensated cirrhosis and were excluded from key calculations of the trial's secondary endpoints.
3. Design flaws in the SYMMETRY trial introduced confounding factors that jeopardized the study's outcomes.
4. The SYMMETRY trial did not align with FDA guidance, as Akero failed to rule out other causes of cirrhosis beyond NASH.
5. Akero misrepresented the trial's potential success and the likelihood that EFX (the treatment being studied) would gain regulatory approval and become a commercial NASH treatment.

These misrepresentations allegedly led to artificially inflated stock prices.

What Can Shareholders Do Now?

If you held Akero Therapeutics shares on or before September 13, 2022, you may have the right to:

• Seek corporate reforms to improve accountability.
• Recover funds spent defending against litigation.
• Qualify for a court-approved incentive award-at no cost to you.

Act Now to Protect Your Rights and Your Investment

Visit: https://grabarlaw.com/the-latest/akero-shareholder-investigation/
Or contact Joshua Grabar directly:

• Phone: 267-507-6085
• Email: [email protected]

#AkeroTherapeutics #AKRO $AKRO #SecuritiesFraud #ShareholderAlert #InvestorRights #ClassAction #CorporateGovernance #LegalAction #GrabarLaw

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/226581